Literature DB >> 8016392

The production of experimental cholecystitis by endotoxin.

D L Kaminski1, W K Feinstein, Y G Deshpande.   

Abstract

Acute acalculous cholecystitis (AAC) is a severe inflammatory disorder of the gallbladder. It occurs primarily in patients acutely ill from other disorders and is related to sepsis and shock. We previously found that platelet-activating factor (PAF), a phospholipid autacoid purported to be a mediator of the shock response, produced AAC. This study was performed to determine the effect of intravenous lipopolysaccharide (LPS) on feline gallbladders. Anesthetized cats underwent LPS administration with and without administration of a cyclooxygenase inhibitor and PAF antagonist. Gallbladder inflammation was evaluated by quantitation of luminal water transport and tissue myeloperoxidase levels. In an attempt to understand the mechanisms of the response, gallbladder perfusate and tissue prostanoid and PAF levels were quantitated as were serum PAF levels. LPS administration resulted in alteration of the normal absorptive pattern of the gallbladder mucosa to exsorption of fluid into the gallbladder lumen, increased tissue myeloperoxidase levels and increased serum PAF levels. This was associated with increased gallbladder tissue and perfusate prostanoid levels and increased perfusate PAF levels. Indomethacin prevented the pro-inflammatory changes in the gallbladder produced by LPS. The PAF antagonist, alprazolam, increased gallbladder prostanoid production when administered alone and with LPS. The administration of LPS resulted in the production of acute changes in the gallbladder consistent with cholecystitis. These changes being prevented by a cyclooxygenase inhibitor suggests that development of AAC may be related to the release of systemic and local pro-inflammatory substances.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016392     DOI: 10.1016/0090-6980(94)90063-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  9 in total

Review 1.  [The intensive care gallbladder as shock organ: symptoms and therapy].

Authors:  C Rimkus; J C Kalff
Journal:  Chirurg       Date:  2013-03       Impact factor: 0.955

2.  Neurochemical characterization of nerve fibers in the porcine gallbladder wall under physiological conditions and after the administration of Salmonella enteritidis lipopolysaccharides (LPS).

Authors:  Krystyna Makowska; Anita Mikolajczyk; Jaroslaw Calka; Slawomir Gonkowski
Journal:  Toxicol Res (Camb)       Date:  2017-10-26       Impact factor: 3.524

3.  Effect of experimental acalculous cholecystitis on gallbladder smooth muscle contractility.

Authors:  H P Parkman; L J Bogar; L L Bartula; A P Pagano; R M Thomas; S I Myers
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

4.  Neurogenic inflammation in cholecystitis.

Authors:  J B Prystowsky; R V Rege
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 5.  Acute acalculous cholecystitis.

Authors:  Philip S Barie; Soumitra R Eachempati
Journal:  Curr Gastroenterol Rep       Date:  2003-08

6.  Lysophosphatidylcholine-stimulated protein and glycoprotein production by human gallbladder mucosal cells.

Authors:  M K Nag; Y G Deshpande; A Li; D Beck; D L Kaminski
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

7.  Incidence of acute cholecystitis underwent cholecystectomy in incidence dialysis patients: a nationwide population-based cohort study in Korea.

Authors:  Hanlim Choi; Soon Kil Kwon; Joung-Ho Han; Jun Su Lee; Gilwon Kang; Minseok Kang
Journal:  Kidney Res Clin Pract       Date:  2021-12-13

8.  The effect of lysolecithin on prostanoid and platelet-activating factor formation by human gall-bladder mucosal cells.

Authors:  M K Nag; Y G Deshpande; D Beck; A Li; D L Kaminski
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

9.  The effect of an interleukin receptor antagonist (IL-1ra) on colonocyte eicosanoid release.

Authors:  G S Smith; C Rieckenberg; W E Longo; D L Kaminski; J E Mazuski; Y Deshpande; T A Miller
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.